From the Research
The primary treatment for autoimmune retinopathy involves immunosuppressive therapy, as evidenced by the most recent and highest quality study 1, which suggests that systemic therapy, local therapy, and biologics can slow disease progression and improve visual outcomes. The treatment approach typically starts with corticosteroids, such as oral prednisone, and may be followed by steroid-sparing immunosuppressants, including mycophenolate mofetil, azathioprine, or cyclosporine. In refractory cases, rituximab or intravenous immunoglobulin may be used. Key points to consider in the treatment of autoimmune retinopathy include:
- Early treatment initiation is crucial to prevent irreversible vision loss 1
- Regular monitoring of visual function, retinal structure with OCT, and antibody levels is essential to assess treatment efficacy 1
- Treatment duration is typically long-term, often lasting years, with dose adjustments based on clinical response and side effects 1
- The goal of therapy is to suppress the abnormal immune response targeting retinal antigens, thereby preventing further photoreceptor damage and vision loss 1 It is essential to note that the treatment of autoimmune retinopathy is highly individualized and may require a multi-disciplinary approach, as suggested by 2.